Dexmedetomidine Supplemented Analgesia and Long-term Survival After Cancer Surgery

NACompletedINTERVENTIONAL
Enrollment

1,500

Participants

Timeline

Start Date

January 6, 2017

Primary Completion Date

December 11, 2024

Study Completion Date

December 11, 2024

Conditions
ElderlySurgeryAnalgesiaDexmedetomidineLong-term Outcome
Interventions
DRUG

Dexmedetomidine supplemented morphine analgesia

Patients in this group receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout time from 6 to 8 minutes.

DRUG

Morphine analgesia

Patients in this group receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout time from 6 to 8 minutes.

Trial Locations (1)

100034

Peking University First Hospital, Beijing

All Listed Sponsors
collaborator

Affiliated Hospital of Hebei University

OTHER

collaborator

Qingdao Municipal Hospital

OTHER

collaborator

The Second Affiliated Hospital of Air Force Medical University

UNKNOWN

collaborator

Beijing Chao Yang Hospital

OTHER

collaborator

Beijing Shijitan Hospital, Capital Medical University

OTHER

collaborator

Beijing Tsinghua Chang Gung Hospital

OTHER

collaborator

Peking University International Hospital

OTHER

collaborator

Beijing Ditan Hospital

OTHER

collaborator

Guizhou Provincial People's Hospital

OTHER

collaborator

The Third Xiangya Hospital of Central South University

OTHER

collaborator

Shaanxi Provincial Cancer Hospital

OTHER

collaborator

Tianjin Hospital of ITCWM-Nankai Hospital

UNKNOWN

collaborator

Zhongda Hospital

OTHER

lead

Peking University First Hospital

OTHER

NCT03012971 - Dexmedetomidine Supplemented Analgesia and Long-term Survival After Cancer Surgery | Biotech Hunter | Biotech Hunter